Focused On-demand Library for Tripartite motif-containing protein 75

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

A6NK02

UPID:

TRI75_HUMAN

Alternative names:

Alternative UPACC:

A6NK02

Background:

Tripartite motif-containing protein 75, encoded by the gene with the accession number A6NK02, is implicated in critical cellular processes. Its primary function is suggested to be associated with female meiosis, a pivotal phase in sexual reproduction where haploid cells are produced from diploid cells. The protein's role, while not fully elucidated, is crucial for the accurate segregation of chromosomes, ensuring genetic diversity and stability.

Therapeutic significance:

Understanding the role of Tripartite motif-containing protein 75 could open doors to potential therapeutic strategies. Its involvement in meiosis suggests that it could be a target for addressing reproductive health issues and genetic disorders. Further research into this protein's function may reveal novel approaches to enhance fertility treatments or combat meiotic diseases.